Navigation Links
Molecule Nutlin-3a activates a signal inducing cell death and senescence in primary brain tumors
Date:4/20/2011

Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53. By this way, it induces cell death and senescence (loss of proliferative capacity) in brain cancer, a fact that slows its growth. These results open the door for MDM2 agonists as new treatments for glioblastomas. The study has been published at the journal PLoS ONE.

Glioblastoma multiforme is the most common brain tumour in adults and the most aggressive. Despite efforts on new treatments and technological innovation in neurosurgery, radiation therapy and clinical trials of new therapeutic agents, most patients die two years after diagnosis. Avelina Tortosa, IDIBELL and University of Barcelona (UB) researcher, coordinator of the study, explained that one objective of her group is "to find substances that sensitize tumour cells to radiotherapy for more efficient treatments".

New therapeutic targets

There is evidence that several genetic alterations promote the growth, invasion and resistance to stimuli that induce programmed cell death (apoptosis). In this sense, the pilot project TCGA (The Cancer Genome Atlas) has sequenced the genome of up to 25 glioblastomas noting that 14% of patients have an increased expression of MDM2 and 35% had alterations in p53 expression (apoptosis-inducing). That is why research is now focused on the development of new therapeutic strategies that target the apoptosis in gliomas.

The aim of this study was to investigate the antitumor activity of Nutlin-3a in cell lines and primary cultures of glioblastoma. Researchers have shown that Nutlin-3a induces apoptosis and cellular senescence by stimulating the p53 pathway in cells, because cells with mutations in this protein don't produce this response. They have also discovered that the use of Nutlin-3a enhances the response of glioblastoma cells to radiotherapy. "The radiation induced DNA damage of tumour cells", explained Tortosa, "the cells activate repairing mechanisms and, if they are unable to repair, they destruct themselves (a mechanism known as apoptosis). With Nutlin-3a we have seen that increases tumour cell death and therefore increases the effectiveness of radiotherapy treatment. "

In conclusion, the results suggest that the MDM2 antagonists may be new therapeutic options for the treatment of glioblastoma patients.


'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related medicine news :

1. Small molecules inhibit growth of human tumor cells
2. Molecules identified that help propel cancer metastasis
3. Scientists identify molecule that can increase blood flow in vascular disease
4. New role for an old molecule: protecting the brain from epileptic seizures
5. Study Links Brain Molecule to Risk of Major Depression
6. Membrane molecule keeps nerve impulses hopping
7. Researchers reveal function of novel molecule that underlies human deafness
8. Small molecules may prevent ebola infection
9. Molecules made by IUPUI students may have potential to cure diseases
10. Link between signaling molecules could point way to therapies for epilepsy, stroke, other diseases
11. Structure of key molecule in immune system provides clues for designing drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Park ... financial planning services to families and business owners in the greater Kansas City ... children with developmental disabilities. , The Lakemary Center is a comprehensive educational resource ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... communications company, launched a new website for its Center for Biosimilars, announced Michael ... include the latest developments in the field of biosimilars through thought leader interaction ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Floundering on ... Heart Month and the perfect time for a reset. The U.S. Apple Association agrees ... to combat many of the factors that contribute to heart disease. , The U.S. ...
(Date:1/17/2017)... ... January 17, 2017 , ... In the crowded Ath-leisure market, ... stand-out company for several differences from other mainstream brands. , Firstly, in ... is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them to have ...
(Date:1/17/2017)... ... 2017 , ... SunView Software’s Service Smart Technology has been selected as a ... , Each year, Pink Elephant recognizes a new product or service developed by an ... problem or opportunity. The award highlights original innovations that were released in 2016, either ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... and KANSAS CITY, Mo. ... Neonatal Consortium (CHNC) has selected Velos and its ... data management and multicenter initiatives. CHNC ... of 32 Neonatal Intensive Care Units at leading ... . The consortium provides a benchmark of care ...
(Date:1/17/2017)... Following an initial analysis, the Senior ... and Drug Administration,s (FDA,s) final regulatory guidance regarding ... Pharmacies and Outsourcing Facilities." In its final guidance, ... -- which would have put patients at risk ... care (LTC) pharmacies.  The agency ...
(Date:1/17/2017)... a letter to President-elect Donald J. Trump , ... priorities for Americans age 50 and older including protecting ... care coverage, and lowering the cost of prescription drugs. ... Trump that "Our nearly 38 million members nationwide and ... their Medicare and Social Security benefits, protect their access ...
Breaking Medicine Technology: